Recent Updates — FDMT
On September 28, 2026, 4D Molecular Therapeutics announced the enrollment of the first patients in its global Phase 3 4SIGHT clinical trial for 4D-150, a gene therapy candidate for diabetic macular edema. The trial involves 514 treatment-naïve patients and aims to demonstrate non-inferiority in visual acuity compared to aflibercept while reducing injection burden. Concurrently, the company released two-year data from the SPECTRA trial showing that patients receiving 4D-150 required significantly fewer supplemental injections than projected for standard of care, with an estimated 75% reduction in treatment burden under Phase 3 criteria. The filing notes FDA Regenerative Medicine Advanced Therapy designation and regulatory alignment for potential Biologics License Application filings based on combined SPECTRA, PRISM, and wet AMD data. 4D Molecular Therapeutics operates as a gene therapy company focused on developing treatments for retinal diseases.
On August 13, 2026, 4D Molecular Therapeutics reported second-quarter financial results showing a net loss of $72.9 million on collaboration revenue of $3.8 million. The company secured a strategic credit facility with Hercules Capital for up to $200 million, drawing an initial $20 million at closing. Cash and marketable securities totaled $430.6 million as of June 30, 2026, sufficient to fund operations into the second half of 2028. Operational highlights include completed enrollment for the Phase 3 4FRONT-2 trial in wet AMD, with topline data expected in H2 2027, and positive two-year PRISM Phase 2b data presented at ASRS. The company plans to initiate a Phase 3 trial for diabetic macular edema in Q3 2026 and will host an Investor Day on October 21, 2026. 4D Molecular Therapeutics is a late-stage biotechnology company developing gene therapies for retinal diseases.
4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 for wet age-related macular degeneration. The trial results showed a 78% overall treatment burden reduction in the overall cohort and an 87% reduction in a recently diagnosed subgroup. 4D Molecular Therapeutics, Inc. is a biotechnology company that develops therapeutic solutions for ocular diseases.
On June 24, 2026, 4D Molecular Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc. for a senior secured term loan facility of up to $200.0 million. The facility matures on June 1, 2031, and includes a $20.0 million Tranche 1A loan drawn on the closing date, alongside several other tranches subject to milestones or discretion. Interest rates are floating, based on the prime rate plus a spread of 2.00% or 2.50%, with a floor of 8.75% or 9.25%. The agreement includes minimum cash covenants and performance covenants tied to FDA approval or revenue targets. The debt is secured by substantially all company assets, including intellectual property. 4D Molecular Therapeutics is a biotechnology company focused on developing molecular medicines.